What is the outlook for CRVO?

The outlook for CervoMed (CRVO) is cautious: 1. **Strong Buy Rating**: CRVO has a "Strong Buy" consensus rating, indicating that analysts believe the stock has potential for price appreciation. 2. **Price Target**: The average price target for CRVO is $44.17, which represents a significant upside from the current price. 3. **Technical Indicators**: The stock's 5-day, 10-day, and 20-day moving averages are $7.2, $8.65, and $9.27, respectively. These indicators suggest that the stock is currently in a downtrend, which could be a bearish signal. |Ticker|Name|Date|Moving Average|code|market_code| |---|---|---|---|---|---| |CRVO.O|CervoMed|20241211|7.1980|CRVO|186| 4. **Resistance and Support Levels**: CRVO's resistance level is $2.8, while the support level is $2.11. The stock is currently trading close to its support level, which could be a point of interest if the stock were to break below this level. |Ticker|Name|Date|Support Level|Resistance Level|code|market_code| |---|---|---|---|---|---|---| |CRVO.O|CervoMed|20241211|1.9016|2.2393|CRVO|186| 5. **MACD and RSI**: The stock's MACD is negative, indicating potential bearish momentum, while the RSI is at 17.65, suggesting that the stock may be oversold. |Ticker|Name|Date|RSI|KDJ|MACD|code|market_code| |---|---|---|---|---|---|---|---| |CRVO.O|CervoMed|20241211|17.6535|-4.4405|-1.2406|CRVO|186| 6. **Financial Performance**: CervoMed reported a net loss of $4.75 million and a diluted EPS of -$0.55 for the quarter ending September 30, 2024. The company's financial performance is currently under pressure. |Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|code|market_code| |---|---|---|---|---|---|---| |CRVO.O|CervoMed|2024 Q1|60.19417475728156|-0.41|CRVO|186| |CRVO.O|CervoMed|2024 Q2|90.18181818181819|-0.27|CRVO|186| |CRVO.O|CervoMed|2024 Q3|21.428571428571416|-0.55|CRVO|186| |Ticker|Name|Date|Total Revenue YoY|Total Revenue|code|market_code| |---|---|---|---|---|---|---| |CRVO.O|CervoMed|2023 Q4||2490578|CRVO|186| |CRVO.O|CervoMed|2024 Q1|66.72372694030975|2347250|CRVO|186| |CRVO.O|CervoMed|2024 Q2|91.22547013158568|3288971|CRVO|186| |CRVO.O|CervoMed|2024 Q3|27.07329663893842|1939751|CRVO|186| |Ticker|Name|Date|Net Income YoY|Net Income|code|market_code| |---|---|---|---|---|---|---| |CRVO.O|CervoMed|2023 Q4|-54.667932434201916|-2362398|CRVO|186| |CRVO.O|CervoMed|2024 Q1|-370.55317253563305|-2514335|CRVO|186| |CRVO.O|CervoMed|2024 Q2|-62.53268149233146|-2316905|CRVO|186| |CRVO.O|CervoMed|2024 Q3|-321.05771028319884|-4753541|CRVO|186| 7. **Risk Warning**: A recent warning highlights that CRVO is at high risk of performing badly due to negative EPS revisions and inferior profitability compared to other Health Care stocks. In conclusion, while CRVO has a positive rating and price target, the technical indicators and financial performance suggest a cautious outlook. Investors should weigh the potential for price appreciation against the risks associated with the stock's current performance and market conditions.